BioLife Solutions is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $25.39 – an increase of 20.79% over the previous week. BioLife Solutions employs 409 staff and has a trailing 12-month revenue of around $147 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $25.39 |
|---|---|
| 52-week range | $11.91 - $28.88 |
| 50-day moving average | $24.00 |
| 200-day moving average | $21.18 |
| Wall St. target price | $30.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.11 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $25.01 from 2024-11-20
| 1 week (2024-11-15) | 18.98% |
|---|---|
| 1 month (2024-10-23) | 13.99% |
| 3 months (2024-08-22) | 2.29% |
| 6 months (2024-05-22) | 14.31% |
| 1 year (2023-11-22) | 84.30% |
|---|---|
| 2 years (2022-11-22) | 16.38% |
| 3 years (2021-11-22) | 45.55 |
| 5 years (2019-11-22) | 48.78% |
Valuing BioLife Solutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLife Solutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioLife Solutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 65.3833. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLife Solutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $147 million |
|---|---|
| Gross profit TTM | $54.1 million |
| Return on assets TTM | -5.97% |
| Return on equity TTM | -15.04% |
| Profit margin | -31.32% |
| Book value | $7.04 |
| Market Capitalization | $975.1 million |
TTM: trailing 12 months
We're not expecting BioLife Solutions to pay a dividend over the next 12 months.
BioLife Solutions's shares were split on a 1:14 basis on 28 January 2014 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLife Solutions shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for BioLife Solutions shares which in turn could have impacted BioLife Solutions's share price.
Over the last 12 months, BioLife Solutions's shares have ranged in value from as little as $11.91 up to $28.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLife Solutions's is 1.883. This would suggest that BioLife Solutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.